January 9, 2014 | Israeli pharmaceutical giant Teva Pharmaceutical Industries has made an offer to acquire American biotechnology company NuPathe for $149 million. NuPathe is developing treatments for various neurological disorders and has a market cap of $100 million.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli Startup Rings Closing Bell At Nasdaq in NYC
March 28, 2024
Israeli, US Companies Unite To Make More Milk From Mushrooms
March 27, 2024
Facebook comments